Company Overview and News

18
Analyzing A Top Energy ETF For Energy Plays

2018-09-21 seekingalpha - 1
If you had owned the SPDR S&P Oil & Gas Exploration ETF, you would have seen 30% in appreciation over the year ended 9/13/18 across 70 stocks.
CRC PBF STT LGCYP UPL LGCYO DNR CVX HFC LGCY REGI UPLMQ OXY

26
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha - 1
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

5
Ultra Petroleum (UPL) Plunges 32% Over a Month: Here's Why

2018-09-07 zacks - 1
Shares of Ultra Petroleum Corporation (UPL - Free Report) have tumbled 31.6% in the past month, underperforming the broader industry’s fall of 5.6%.
HLX UPL ALLY MDR UPLMQ MCDFF

11
Will Ultra Petroleum File For Bankruptcy Again As Stock Drops Over 90%

2018-08-13 seekingalpha - 5
Ultra Petroleum Corp (UPL) is in trouble. After exiting Ch.11 in April 2017, they still have way too much debt. Recently management announced problems with their expensive horizontal drilling and that they are selling their Utah oil assets for only $75 million, which they paid $650 million. The stock price has plunged from the Ch.11 estimated equity plan value for new UPL shares of $17.30 to only $1.
UPL REXX BBPPQ RXNRP REXXQ BBEP UPLMQ BBEPQ BBEPP

4
Ultra Petroleum Corp. (UPL) CEO Bradley Johnson on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day, everyone, and welcome to today's Ultra Petroleum Second Quarter 2018, Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] Please note this call is being recorded.
UPL UPLMQ MS

10
Coty, e.l.f Beauty Sink into Thursday’s 52-Week Low Club

2018-08-09 247wallst - 1
August 9, 2018: Here are four stocks trading with heavy volume among 96 equities making new 52-week lows in Thursday’s session. On the NYSE decliners and advancers traded even and on the Nasdaq, advancers led decliners by about 1.05 to 1.
ACAD UPL UPLMQ ELF COTY

4
UPL / Ultra Petroleum Corp. 10-Q (Quarterly Report)

2018-08-09 sec.gov
upl-10q_20180630.htm UNITED STATES
UPL

4
Ultra Petroleum Corp. 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by Ultra Petroleum Corp. in conjunction with their 2018 Q2 earnings call.
UPL UPLMQ

30
Plug Power (PLUG) Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 zacks
Plug Power (PLUG - Free Report) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
GD UPL BSTC UPLMQ PLUG

30
Ultra Petroleum (UPL) Misses Q2 Earnings and Revenue Estimates

2018-08-09 zacks
Ultra Petroleum (UPL - Free Report) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
GD UPL BSTC UPLMQ PLUG

30
BioSpecifics Technologies (BSTC) Q2 Earnings Top Estimates

2018-08-09 zacks
BioSpecifics Technologies (BSTC - Free Report) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.
GD UPL BSTC UPLMQ PLUG

34
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates

2018-08-09 zacks
Agenus (AGEN - Free Report) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
GD UPL BSTC AGEN UPLMQ PLUG

30
Veritiv (VRTV) Lags Q2 Earnings Estimates

2018-08-09 zacks
Veritiv (VRTV - Free Report) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items.
GD UPL BSTC VRTV UPLMQ PLUG

4
UPL / Ultra Petroleum Corp. FORM 8-K (Current Report)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
UPL

5
Ultra Petroleum Announces Second Quarter 2018 Results, Provides Update on Horizontal and Vertical Program

2018-08-09 globenewswire - 1
HOUSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Ultra Petroleum Corp. (NASDAQ: UPL) announces financial and operating results for the quarter ended June 30, 2018.
UPL UPLMQ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to UPL / Ultra Petroleum Corp. on message board site Silicon Investor.

I need to quintuple $20,000 I need to quintuple $20,000 I need to quintuple $20,000 Ultra Petroleum (UPL) Ultra Petroleum (UPL) Ultra Petroleum (UPL)
Financialsense (FSO) - Jim Puplava forum Financialsense (FSO) - Jim Puplava forum Financialsense (FSO) - Jim Puplava forum Ultra Petroleum Corp (UPL) Ultra Petroleum Corp (UPL) Ultra Petroleum Corp (UPL)
Duplicate Duplicate Duplicate SCS Solars Computing Systems (Duplicate) SCS Solars Computing Systems (Duplicate) SCS Solars Computing Systems (Duplicate)
Making Couplets for Fun Making Couplets for Fun Making Couplets for Fun Unwired Planet (www.uplanet.com) Unwired Planet (www.uplanet.com) Unwired Planet (www.uplanet.com)
BFLYand XCMC will zoom in next couple of days BFLYand XCMC will zoom in next couple of days BFLYand XCMC will zoom in next couple of days A COUPLE BIG MOVERS!!! A COUPLE BIG MOVERS!!! A COUPLE BIG MOVERS!!!
CUSIP: 903914208